About: http://data.cimple.eu/news-article/5acc47683ab215098aec85ebb78556859db60edddd95c6d16b8a3d85

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/5acc47683ab215098aec85ebb78556859db60edddd95c6d16b8a3d85 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US pharmaceutical giant Gilead Sciences confirmed Sunday that it is buying American biotech firm Immunomedics, which makes a breast cancer drug, for $21 billion. Under the transaction, to be finalized in the fourth quarter of 2020, Gilead will buy Immunomedics at a price of $88 per share, more than double the current value of $42.25. The California drug giant plans to fund the transaction with $15 billion in cash and $6 billion in new bonds. "This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio," Gilead Chairman and CEO, Daniel O'Day said in a statement. New Jersey-based Immunomedics makes Trodelvy, an antibody drug approved in April by the FDA, which is used to treat triple-negative breast cancer, a particularly aggressive form of the disease. Triple-negative breast cancer represents about 10 to 15 percent of all breast cancers, according to the American Cancer Society. Studies are underway to assess the efficacy of Trodelvy in treating lung and bladder cancer. Immunomedics stock has jumped more than 90 percent on Wall Street since Trodelvy's approval. Gilead took a giant step forward in the rapidly developing oncology sector with its $4.9 billion April acquisition of Forty Seven, which is developing a promising treatment for blood cancers. dho/mdl/bfm
schema:headline	Gilead in $21 bn deal for Immunomedics
schema:mentions	American Cancer Society Bladder cancer Oncology Tumors of the hematopoietic and lymphoid tissues Pharmaceutical industry Lung cancer Seven Network Breast cancer Antibody Food and Drug Administration Chief executive officer California United States Immunomedics Triple-negative breast cancer Daniel O'Day Gilead Sciences Radio in New Zealand
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-09-14 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	74 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software